COVID-19: How effective are the repurposed drugs and novel agents in treating the infection?

Document Type

Article

Publication Date

1-1-2022

Abstract

Coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has impacted the lives and wellbeing of many people. This globally widespread disease poses a significant public health concern that urges to discover an effective treatment. This review paper discusses the effectiveness of repurposed drugs used to treat COVID-19 and potential novel therapies for COVID-19. Among the various repurposed drugs, remdesivir is the only agent approved by the Food and Drug Administration (FDA) to treat COVID-19. On the other hand, several drugs have been listed in the Emergency Use Authorization (EUA) by the FDA to treat COVID-19, including casirivimab and imdevimab, baricitinib (in combination with remdesivir), bamlanivimab, tocilizumab, and IL-6 inhibitors. In addition, in vitro and clinical studies have suggested cepharanthine, sotrovimab, and XAV-19 as potential treatments to manage COVID-19. Due to inadequate understanding of COVID-19 and the rapid mutation of SARS-CoV-2, COVID-19 remains a threat to global public health, with vaccination considered the most effective method to decrease COVID-19 transmission currently. Nevertheless, with the intense efforts of clinical researchers globally, more promising treatments for COVID-19 will be established in the future. © 2022, Knowledge E. All rights reserved.

Keywords

Antiviral agents, COVID-19, Drug repurposing, SARS-CoV-2, Treatment

Publication Title

Sudan Journal of Medical Sciences

Divisions

pharlife

Funders

Ministry of Higher Education, Malaysia,FRGS/1/2019/SKK09/TAYLOR/03/1

Volume

17

Issue

4

Publisher

Knowledge E

Additional Information

Cited by: 0; All Open Access, Gold Open Access

This document is currently not available here.

Share

COinS